公开(公告)号：US20160003804A1

公开(公告)日：2016-01-07

申请号：US14542453

申请日：2014-11-14

Applicant: Synta Pharmaceuticals Corporation

Inventor： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

IPC: G01N33/50 ,  G01N33/68

CPC classification number: G01N33/5035 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2333/54 ,  G01N2500/10

Abstract: The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

Abstract translation: 本发明涉及用于调节c依赖性依赖性细胞因子产生的组合物和方法，而不会实质性地改变NF和κB的表达水平和/或I＆Kgr B的量。 本发明还涉及通过测定c-Rel的改变的亚细胞定位确定的c-Rel活性调节剂的筛选，但其中NF和κB的表达水平和/或I＆Kgr B的量在实质上未改变。

公开(公告)号：US09910031B2

公开(公告)日：2018-03-06

申请号：US14542453

申请日：2014-11-14

Applicant: Synta Pharmaceuticals Corporation

Inventor： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

IPC: G01N33/50 ,  G01N33/68

CPC classification number: G01N33/5035 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2333/54 ,  G01N2500/10

Abstract: The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.